![Hong Sheng Xu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hong Sheng Xu
Directeur Général chez Shapuaisi Qiangshen Pharma Co., Ltd.
Postes actifs de Hong Sheng Xu
Sociétés | Poste | Début | Fin |
---|---|---|---|
Shapuaisi Qiangshen Pharma Co., Ltd.
![]() Shapuaisi Qiangshen Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Jilin Yueshi Tianbo Pharmaceutical Co., Ltd., Shapuaisi Qiangshen Pharma Co., Ltd. manufactures tablets, hard capsules, and granules. The company is based in Dongfeng County, China. The Chinese company was founded in 2014. The CEO is Hong Sheng Xu. Shapuaisi Qiangshen Pharma Co. was acquired by Jilin Yueshi Tianbo Pharmaceutical Co., Ltd. from Zhejiang Shapuaisi Pharmaceutical Co. Ltd. on January 26, 2022 for $12.50 million. | Directeur/Membre du Conseil | - | - |
Directeur Général | - | - |
Historique de carrière de Hong Sheng Xu
Anciens postes connus de Hong Sheng Xu
Sociétés | Poste | Début | Fin |
---|---|---|---|
ZHEJIANG SHAPUAISI PHARMACEUTICAL CO.,LTD. | Directeur/Membre du Conseil | 25/09/2018 | - |
Président | 25/09/2018 | - |
Statistiques
Internationale
Chine | 3 |
Opérationnelle
Director/Board Member | 2 |
Chairman | 1 |
Chief Executive Officer | 1 |
Sectorielle
Health Technology | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
ZHEJIANG SHAPUAISI PHARMACEUTICAL CO.,LTD. | Health Technology |
Entreprise privées | 1 |
---|---|
Shapuaisi Qiangshen Pharma Co., Ltd.
![]() Shapuaisi Qiangshen Pharma Co., Ltd. Pharmaceuticals: MajorHealth Technology Part of Jilin Yueshi Tianbo Pharmaceutical Co., Ltd., Shapuaisi Qiangshen Pharma Co., Ltd. manufactures tablets, hard capsules, and granules. The company is based in Dongfeng County, China. The Chinese company was founded in 2014. The CEO is Hong Sheng Xu. Shapuaisi Qiangshen Pharma Co. was acquired by Jilin Yueshi Tianbo Pharmaceutical Co., Ltd. from Zhejiang Shapuaisi Pharmaceutical Co. Ltd. on January 26, 2022 for $12.50 million. | Health Technology |
- Bourse
- Insiders
- Hong Sheng Xu
- Expérience